Posted by Michael Wonder on 15 Oct 2022
BeiGene receives positive CHMP opinion for Brukinsa (zanubrutinib) for the treatment of adults with CLL
14 October 2022 - If approved, Brukinsa would be the only BTK inhibitor for chronic lymphocytic leukaemia in the European Union to achieve superior efficacy versus standard of care in head to head trials.
BeiGene today announced that the CHMP of the EMA has issued a positive opinion recommending approval of Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukaemia.
